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PREFACE
The main body of this thesis in Chapter III is a journal article entitled “Ciprofloxacin and
Rifampin Dual Antibiotic-Loaded Biopolymer Chitosan Sponge for Bacterial Inhibition.” This
manuscript was submitted as an invited supplement to the Journal of Military Medicine.
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ABSTRACT
Increases in patients’ costs, multiple surgeries, and difficult treatment solutions are
resultants of musculoskeletal infections. The presence of biofilm-forming or antibiotic resistant
bacteria exponentially increase the complexity and complications in treatment of those
musculoskeletal infections. During this study, the combination of ciprofloxacin and rifampin
loaded in and released from chitosan-based local delivery systems was evaluated as an adjuvant
therapy for prompt reduction of biofilm-forming bacteria in the wound when locally delivered.
Primary assessments included antibiotic release, sponge eluate in vitro activity, in vitro synergy
assays, effect on chitosan sponge pore structure, and an in vivo implant associated biofilm
functional model. Antibiotic activity was present through seven days against S. aureus and P.
aeruginosa. Ciprofloxacin had a therapeutic elution profile that lasted, at least, seven days while
rifampin’s lasted three days. Additive effects were present against P. aeruginosa during the in
vitro synergy assay with inconclusive results against S. aureus. No unexpected or adverse effects
on chitosan sponge pore structure were seen after sponges were loaded with the antibiotic
cocktail. Complete clearance of biofilm-forming S. aureus and E. coli with no noticeable adverse
effects were achieved in the functional infected pin murine model. The results of this study
support the potential use of ciprofloxacin and rifampin in chitosan-based and other local delivery
devices, as local adjunctive therapy, for prevention of musculoskeletal and surgical site
infections.
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CHAPTER I
INTRODUCTION
Statement of Clinical Problem
Of all injuries in the United States one of the more prevalent types are complex
musculoskeletal wounds, which may experience compromised wound healing as a result of
bacterial infection.1 Civilians are estimated to have a 20% chance of infection in open fracture
wounds with soldiers having estimates up to 65% if an open fracture wound is the result of a
high-energy trauma.1-3 Bone fixation devices may be required to ameliorate traumatic injuries to
the musculoskeletal system. According to estimates, incidences of open fracture and extremity
trauma are estimated to be six million or more each year in the United States.4 Infection rates of
5% are seen when fixation devices are implemented in musculoskeletal injuries.5 Recently
released estimates from the American Academy of Orthopedic Surgeons (AAOS) reflect over
500,000 surgical site infections (SSI) occurring per year subsequent to an orthopedic procedure.6
It was reported between October 2005 – December that 14.8% of total hip arthroplasty (THA)
revisions were due to infection.7 Occurrence of bacterial resistance is increasing, magnifying an
already difficult treatment prospect of musculoskeletal infections.6 Adverse effects may result
from an increase in systemic antibiotic administration.8 Some current solutions such as
poly(methyl methacrylate) beads offer minimal to no degradation, requiring an additional
surgery for removal.9, 10 Treatment solutions incorporating calcium sulfate may experience the
onset of excessive fluid accumulation and wound drainage resulting from rapid degradation.11
Engineered inexpensive biodegradable devices, loaded with widely available antibiotics, could
be advantageous to reduce or prevent SSIs in orthopaedic procedures and especially in

conjunction with the regimen aimed at complex extremity wounds coalesced with fracture
fixation devices.
Hypothesis and Research Objectives
It was hypothesized that engineered porous chitosan sponges, after being hydrated with
ciprofloxacin and rifampin for short-term treatment, less than 14 days, will be effective as an
adjunctive therapy for infection inhibition. Other goals include maintaining elution kinetics to
maintain diffusion of active antibiotics to inhibit establishment of bacterial infections in
musculoskeletal injuries, cytocompatibility, and capability of point-of-care loading. The specific
objectives of this research are as follows:
1. Maintain bactericidal activity at or above minimal inhibitory concentrations against
biofilm-forming P. aeruginosa and S. aureus of ciprofloxacin and rifampin after being
eluted from chitosan-based local delivery device
2. Possess biodegradable characteristics in chitosan-based sponges that will eliminate need
of additional surgery for removal, after application, of local delivery device
3. Possess cytocompatibility/biocompatibility properties of chitosan-based local delivery
device that support use in infection prevention applications
4. In vitro delivery of ciprofloxacin and rifampin from the chitosan-based sponges sustained
through, at least, 7 days at active levels against biofilm-forming S. aureus and P.
aeruginosa to prevent colonization
5. In vivo delivery of ciprofloxacin and rifampin from chitosan-based sponges over, at
minimum, 7 days for inhibition of bacterial infection resulting from biofilm-forming S.
aureus and E. coli in a functional mouse pin model
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CHAPTER II
LITERATURE REVIEW
Wounds and Healing Process
Musculoskeletal wound infections may develop from traumatic injuries, surgical wounds,
acute wounds lacking proper treatment, or from an accompanying co-morbidity; and may
prevent normal patient healing and recovery.12 Peripheral vascular disease, diabetes,
malnutrition, and chronic steroid use are some co-morbidities which can impair tissue healing
and contribute to the occurrence of surgical site and wound infections.13 High-energy fractures
where the bone penetrates the skin, compromises vasculature and communicates with extratissue environment—open fracture—is an extreme case of traumatic musculoskeletal wound.14
Open fractures are more likely to establish bacterial colonization when compared to surgically
created wounds.15 Emotional, physical, and monetary stress experienced by the patient resulting
from musculoskeletal wounds are also high.7
Impairment of normal physiology resulting from damage to muscle, skin, bone, or other
tissue is referred to as a wound.16 Innate responses in efforts to repair the wound occurs in a
series of six steps normally. Rapid hemostasis is primary after a wound is initiated, which is the
mechanism that stops the bleeding.16 Vasoconstriction, tight closing of blood vessels, of wound
feeding vessels and clotting are the body’s mechanisms normally used to achieve this goal.16
Inflammation is the body’s way to signify an injury it is secondary/simultaneous to hemostasis.
Healthy cells are being directed to the wound site during the process of inflammation and is one
reason why inflammation is vital in the wound care process.16 However, inflammation can be
detrimental to wound healing by preventing regeneration if it prolongs. There are four primary
symptoms associated with inflammation, redness, swelling, heat, and pain. As inflammation is
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occurring several types of cells are being released including ones for migration and proliferation.
Movement of cells in an extremely coordinated and specific order happens with migration
function. Further constriction of blood vessels, like hemostasis, happens under proliferation. As
bleeding becomes controlled the body begins engaging in rebuilding tissue. The formation of
new blood vessels during a process referred to as angiogenesis is the primary step in the
rebuilding process. Damaged veins and arteries are beginning to be replaced through either
creation of new sections or with addition to existing sections. After angiogenesis is the
replacement of compromised skin, known as re-epithelialization. Keratinocytes, which comprise
the epidermis, are proliferating and migrating to cover the wound from the environment during
this phase.16 During this phase, several layers are created each working in tandem to prevent loss
of fluid and provide protection.16 These are innate would healing processes that most humans
possess and employ if a wound is experienced. There are several instances when the innate
processes may be overwhelmed and require an assist, some musculoskeletal wound infections
are a prime example.
Various cells types have specific roles in hemostasis, inflammation, proliferation, and
remodeling, which are aspects of innate wound healing.17 Neutrophils migrate from the blood to
remove foreign bodies, bacteria, non-viable tissue and other debris from the wound site within
the first eight hours.18 Maximal concentration of neutrophils at the site of the wound is reported
to occur in 24 – 48 h with decreased concentration beginning 72 h after wound induction.19
Macrophages and mast cells become responsible for the cleansing process as neutrophils
evacuate the wound site.20 Epithelial cells construct a thin epithelial layer over the wound,
closing it from the external environment after the wound is clean and disinfected, which occurs
approximately after 48 – 72 h.21, 22 Subsequent to the cellular/tissue responses discussed
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previously, remodeling is initiated and persists, on average, 4 – 8 weeks depending on the
severity of the wound.23
Wound Management
Effective management of the wound can assist the patient’s innate response in restoration
of function to the wound site. A reduction in morbidity with improved prognosis is seen through
the prevention of complications in the healing process.24 Debridement, irrigation, fixation,
closure and infection prevention are main principles of complex musculoskeletal wound
management.25 Currently, no universal standard exists in application of these principles by
surgeons.26
The process of debridement removes foreign and non-viable tissue from the wound.27
Necrotic tissue is the ultimate product of non-viable tissue and inhibits wound healing with the
promotion of microbe growth and the blockage of the host’s inherent tissue defenses.27 As a
result, debridement of skin and subcutaneous tissue is executed until capillary bleeding is
visualized.26 Additional debridement may be recommended after 24 – 48 h depending on the
degree of soft tissue damage or contamination.28
Removal of smaller foreign bodies coupled with the reduction in bacterial concentration
is known as irrigation or lavage. While there is some variation in irrigation procedures, in
general copious amounts (approximately 10 L) of irrigation fluid are used to help remove small
foreign bodies and bacteria from wound site.28 When ballistic or explosion wounds are present
irrigation is essential due to the potential for the bacteria to spread along tissue planes.29 In
efforts to minimize patient infection, antimicrobial administration by means of irrigation also
may be implemented.30 The knowledge level of the presiding surgeon regarding the wound
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affords them the opportunity to tailor the antibiotic lavage treatment for specific suspected
bacterial contaminate.31
Further bone and soft tissue damage is inhibited by wound fixation and closure, which
provides an initiation point for inherent wound healing procedures.32 Several methods for
internal fracture stabilization exist including, but not limited to, intramedullary nails, plates and
screws with each possessing pros and cons.33 Intramedullary nails are effective when fixation of
lower extremity fractures are sought, however there are possibilities that bone circulation may be
disrupted.34, 35 Plates and screws are often employed when precision is needed for a fractured
bone alignment and are mostly used in upper extremity and transarticular fractures.36, 37 For more
advanced wounds entailing crushed or pulverized bone and surrounding soft tissue damage,
treatment solutions may include internal fixation devices such as rods and scaffolds composed
from titanium or stainless steel alloys or external devices consisting of frame and pins.38, 39 When
considering prosthesis associated with surgical procedures performed during total hip and total
knee arthroplasties material fixation becomes critical.40 Closure of wounds may be achieved with
available soft tissues, depending on whether adequate coverage is possible, or soft tissue
reconstruction from local or free muscle flaps.32 The surgeon may, ultimately, be constricted to
amputation due to damage or infection.28
Wound Infection
Prevention is often the most desired goal in infection treatment, however approximately
65% of patients with severe, open wounds have microorganism contamination.2
Among the six million fractures occurring every year, 5 – 10% will entail additional treatment
for compromised healing resulting from improper fracture fixation, bone resorption, vascular
impairment or infection. Infection risks are increased if co-morbidities preexist and once
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infection is established symptoms may include fever, chills, headache and stiffness to pain,
erythema and wound drainage.2 Imaging, microbiological cultures, blood tests, and polymerase
chain reaction (PCR) techniques are infection diagnostic tools.41-43 Systemic antibacterial therapy
is a technique that does not involve surgery as an initial treatment.44 Long term effects of wound
infections include revision surgeries, continued antibiotic treatments, possible recurrence of
infection, prolonged wound healing and reduced quality of life, which all contribute to increased
medical costs.42 Potential clinical outcomes include patient death or treatment failure.45, 46 Within
the United States surgical site infections (SSI) are accountable for an approximate $1.6 billion
inflation in healthcare costs per year.47 Estimates for average attributable costs of SSIs include
estimates ranging from $10,443 (2005 dollars)48 to $25,546 (2002 dollars)49 per infection.
According to a Centers for Disease Control and Prevention report by Scott et al., the infection
site with the largest range of annual costs is SSI $3.2 billion to $8.6 billion using the Consumer
Price Index for all urban consumers (CPI-U) and $3.5 billion to $10 billion using the Consumer
Price Index (CPI) for inpatient hospital services.50 The CPI-U is constructed by the U.S Bureau
of Labor Statistics and is a measure of the average change over time in prices paid by all urban
consumers (defined as all urban households in Metropolitan Statistical Areas and in urban places
of 2500 inhabitants or more) for a market basket of consumer goods and services purchased for
day-to-day living.50
Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis) and
Pseudomonas aeruginosa (P. aeruginosa) are common in musculoskeletal wounds.2 Often
isolated from the skin and gastrointestinal (GI) tract of healthy individuals’ flora with the ability
to cause disease when introduced to wound sites.2 S. aureus is commonly found in
musculoskeletal infections consisting of osteomyelitis, arthritis, myositis, or implanted
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orthopaedic devices and arises in roughly 50% of all infections.2, 51 S. aureus is reported as the
leading cause of osteomyelitis and nongonococcal bacterial arthritis52 and a prominent cause of
prosthetic joint infection.2, 5 Escalation of the problem was seen in the 90’s as S. aureus began to
exhibit resistance to certain antibiotics.45 S. aureus resistance nullifies the effectiveness of many
β-lactam antibiotics, including methicillin specific antibiotics, which act to inhibit Gram-positive
bacteria’s peptidoglycan cell wall synthesis.42 Methicillin resistant Staphylococcus aureus
(MRSA) infections have seen an increase from 35.9% in 1992 to 64.4% in 2003 for S. aureus
isolates collected in the United States.45, 46 The American Academy for Orthopedic Research
recently indicated the death rate from MRSA is 2.5 times greater than its non-resistant
counterpart.5 Propagation of vancomycin resistant S. aureus (VRSA) is a grave concern.53, 54 The
resistance to vancomycin by S. aureus has seen increasing importance in nosocomial pathogens
in the United States, but to date has seen little occurrence in osteomyelitis.55
The commonly reported infection rate through prophylactic antibiotics and aseptic
techniques for uncontaminated surgical wounds is 1%, however for open fractures the rate is
approximately 50%.12 A wide-spectrum of Gram-positive and Gram-negative specific
antimicrobial agents are commonly administered to open fracture wounds to prevent
contamination. Bacteria may adhere to wound tissue and on implanted biomaterial surfaces
subsequently forming an enclosed film of polysaccharides, ions, nutrients, and other
environmental constituents as a mechanism of survival.56 Adhered bacteria are known as biofilm.
According to reports the increase in biofilm related bacterial resistance is amplified by the
increase in betalactamase concentration within the biofilm and the inability of antibiotic to
penetrate biofilm.5 The presence of implant devices strengthens the likelihood of infection and
biofilm, making implant materials an infection risk factor.56, 57
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Implant Associated Infection
Host defense weaknesses that allow bacteria to become established are exploited in
orthopaedics with implant concomitant post-surgical infections.56 Currently, simple debridement
and irrigation procedures allied with antimicrobial agents are not always efficacious in
prevention of infection specifically with open fractures, which have an infection rate of 50%.14, 58
Due to the large population of patients receiving orthopaedic implants with an infection rate of 1
- 5% for those involving total joint replacement, infections related to implants are considered
prime for novel research in infection prevention treatments.5, 7, 56 Often, additional surgeries for
implant removal and replacement are the only option for infection eradication. Bacteria are
passively or actively adsorbed after implantation on biomaterial surfaces leading to biofilm
formation. One fundamental pathogenic mechanism in biomaterial-centered sepsis is microbial
colonization followed by adjacent tissue damage.56 Main pathogenic species of orthopaedic
clinical isolates related to infections linked to implants are 34% S. aureus, 32% S. epi, 13%
coagulase negative staphylococci, 6% pseudomonas, 5% enterococcus, and 11% other species.2
A vast majority of infections associated with implants in orthopaedics are the result of Grampositive aerobes, primarily staphylococci.6
Increases in morbidity, mortality and socioeconomic costs can be attributed to
biomaterial-centered infections.47 Preventing infection formation is an ongoing and growing
challenge to implant development.28, 56 Areas for improvement include more efficacious
antibiotic treatment of implant associated infections and traumatic musculoskeletal wounds.
Antibiotic Therapy
Selection of antibiotics for the treatment of musculoskeletal infection may be
distinguished by three phases: 1st visual, 2nd definitive treatment, and 3rd treatment
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confirmation.59 The risk of infection in patients with severe wounds is reduced with early
antibiotic administration.44 The selection of antibiotics by the attending physician or clinician is
constrained by their ability to target the bacteria commonly seen in infections that the patients
are deemed to be at risk for. Increases in the occurrence of antibacterial resistance magnifies the
arduous task of combating musculoskeletal wound infections.44 Due to recent advancements,
wound screening has the ability to identify the presence of certain microbes prior to treatment.6,
41

With early dispensation of selected antibiotic therapy the effectiveness has improved, aiding in

limiting exposure and preventing infection.59
Quinolones/fluoroquinolones have proven to be effective against Gram-negative and
some Gram-positive bacteria due to their ability to prevent the DNA from unwinding and
duplicating.60 Principally, quinolones/fluoroquinolones target DNA gyrase and topoisomerase
IV, which are both bacterial type II topoisomerases.61 DNA gyrase is a tetramer enzyme with
two GyrA and two GyrB subunits that catalyze the introduction of negative superficial turns into,
and elimination of positive supercoils from, the replication fork into the double-stranded
covalently closed circular DNA.62 DNA gyrase acts before the replication fork, preventing
replication-induced structural changes.63 Topoisomerase IV acts behind the replicating fork and
catalyzes the removal of supercoils and decantation of interlocked daughter DNA molecules.64
Both DNA gyrase and topoisomerase IV appear to be targeted by all quinolones, regardless of
bacterial species.62 In Gram-negative bacteria, DNA gyrase is generally bound more readily by
quinolones.62 Topoisomerase IV is preferred in Gram-positive bacteria.65, 66 Although this effect
on bacteria by quinolones has proven useful and have successfully prevented the duplication of
certain bacteria, quinolones alone have proven ineffective, comparable to other classes of
antibiotics, against biofilm when used alone.67-71 Ciprofloxacin is a 2nd generation
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fluoroquinolone that has been clinically effective at inhibiting Gram-negative and some Grampositive bacteria.67-76 Second-generation quinolones are fluorinated quinolones discovered in the
mid-1980s.62 The fluorine atom and piperdine positioning result in a much broader spectrum of
activity that includes P. aeruginosa and some Gram-positive bacteria, such as S. aureus, and
improved bioactivity.62 While ciprofloxacin has shown the ability to penetrate biofilm, bacterial
resistance has also been developed.77 Ciprofloxacin is one of the numerous fluoroquinolones that
have extensive clinical usage for the treatment of Gram-negative and some Gram-positive
bacterial pathogens.63, 65, 66, 78-83 Potential acquired resistance to ciprofloxacin, along with
massive list of other antibiotics, presents challenges that require novel approaches.60, 67, 68, 84-95
Among these novel approaches is the usage of antibiotics in combinations that may facilitate
possible synergism of each antibiotic’s active mechanism against polymicrobials. However,
systemic administration of ciprofloxacin has recently been noted to cause adverse side-effects
involving tendons, muscles, joints, nerves and the central nervous system by the FDA.96
Rifampin has emerged as a major player in antibiotic combination therapy for its ability
to combat biofilm among other infections. Rifampin, a type of rifamycin, specifically inhibits
bacterial DNA-dependent RNA polymerase by blocking the RNA chain initiation step of
bacterial DNA transcription to messenger RNA that is needed to synthesize bacterial proteins.97
Rifampin is employed as part of combination regimens against mycobacterial infections and
some Gram-positive bacterial infections, such as S. aureus and S. epidermis.62 Rifampin is
bactericidal against Gram-positive bacteria and diffuses well into biofilm where it perpetuates its
bactericidal ability.62 Disruption of biofilm is within the scope of rifampin, however rifampinresistant mutants may be selected.62 Rifampin requires administration in conjunction with other
antibiotics as a result.62 Prior in vitro studies have demonstrated rapid synergy when rifampin is
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incorporated with a β-lactam and slower synergy with vancomycin.89, 97, 98 Synergy is defined in
the medical dictionary as the correlated action or cooperation by two or more structures or drugs.
Synergism is the state at which the combined action is greater than the sum of each acting
separately. Rifamycins bind very tightly to the β-subunit of the RNA polymerase in a molar ratio
1:1.62 In contrast they do not bind well to the β-subunits isolated from rifamycin-resistant
mutants and mutations are found in the β-subunits of RNA polymerase in such mutants that aid
in a reduction of rifampin binding to β-subunits of RNA polymerase.62 There is currently no
evidence to support an effect on mammalian enzymes by rifampin.62 Rifamycins also modify
bacterial pathogenicity and may alter attachment and tissue toxicity.99-101 The World Health
Organization’s List of Essential Medicines includes rifampin and ciprofloxacin. Multiple
investigations are ongoing consisting of rifampin in combination with other infection reducing
agents.88, 89, 102-116 Resistance to rifampin, despite its contrivance, has been demonstrated to
develop quickly.56, 117-120 Monotherapy is rarely incorporated as a result.56, 117-120 Due to their
methods of action, antibiotics must be in contact with their bacterial targets to be effective.121, 122
Some antibiotics may be delivered to the infection site either systemically or locally, while some
are delegated to being delivered locally.123
Localized Drug Delivery
Drug delivery using intravenous or oral routes is well established, however those
methods may possess undesired effects related to the distance from the injection site or digestive
system; in addition to the biochemical environment that must be navigated before the drug
reaches the wound.124 The success of antibiotic therapy depends on keeping low, nontoxic levels
systemically and high levels in the infection tissue.8 Local therapy using antibiotic-loaded
delivery vehicles have been utilized adjunctive to systemic antibiotic therapy for open wound
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and fracture treatments. Antibiotic release from the delivery mechanism into the surrounding
tissue is referred to as elution, which is facilitated by increased surface area/volume ratio and
high concentrations of loaded antibiotics.124 Protracted release of drugs, which may lead to high
local levels of bioactive antibiotics with negligible serum levels are obtainable using this
technique.125 Bone penetration is not actively observed with systemically administered
antimicrobial agents, in contrast high local levels of antibiotics enable antibiotic delivery through
diffusion to bone and avascular areas of wounds.8 Through the utilization of local drug delivery
potency is maximized at infection site, while minimizing systemic toxicity risk generating an
efficacious delivery system.10
Efficacy of local drug delivery may be improved with the insertion of local biodegradable
delivery devices.126 Biodegradable materials are broken down with hydrolytic mechanisms with
or without supplemental enzymatic mechanisms. A primary advantage of biodegradable systems
is the circumvention of subsequent surgeries to remove the foreign drug delivery device.
Implantation at the site of the wound allows the drug to be delivered at amplified concentrations
with minimal delay between delivery and action, with degradation occurring naturally over time.
The reported status of local drug delivery in an article by McLaren, stated that all are pre-loaded
with antibiotics during the manufacturing process, referred to PMMA and calcium sulfate
(CaS).10 McLaren concluded that no polymer was easily mixed with antibiotics in the operating
room or in situ-loaded for clinical use.10 In situ-loading would offer the advantage of being
implemented locally at the site of the wound or infection at the time of treatment, which chitosan
sponge based local delivery systems offer.
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Chitosan
Chitosan may be used to fabricate local biodegradable delivery devices. Chitosan is a
linear polysaccharide composed of randomly distributed β-(1-4)-2-amino-2-D-glucosamine
(deacetylated) and β-(1-4)-2-acetamido-2-D-glucoseamine (acetylated) units.127 The second most
abundant naturally occurring polymer, chitin, is used to derive chitosan.128 Chitin is a white, hard
and inelastic nitrogenous polysaccharide that is isolated from exoskeletons of crustaceans. Strong
alkaline solution is the major procedure used for obtaining chitosan by alkaline deacetylation of
chitin.129 The raw material is crushed, washed with water or detergent and ground into small
pieces prior to processing. The abundance of acetyl units is the chemical difference between
chitosan and chitin. Chitosan’s performance is impacted by its degree of deacetylation (DDA).130,
131

When the DDA is greater than 50% the copolymer is termed chitosan. Chitosan possesses a

weak cationic base, is insoluble in water and organic solvents but is soluble in dilute acidic
solutions, which may include acetic, citric, formic or lactic acid.130, 132 Negatively charged
surfaces are bound by chitosan due to bioadhesive properties resulting from its charges
(NH3+).133 Chitosan is characterized as biodegradable,128, 134, 135 antibacterial127, 136 and possesses
ability to be loaded with and release drugs over time.124, 136-138
The level of chitosan’s DDA affects degradability with DDA close to 50% being highly
degradable in vivo, however when DDA is greater than 95% chitosan may remain in vivo for
months even years.139 Lysozyme, N-acetyl-o-glucosamindase, and lipases degrade chitosan
within the body. Lysozyme degrades chitosan by cleaving the glycosidic bonds between the
repeating units, with byproducts of saccharides and glucosamines which are incorporated into
glycoproteins or excreted as carbon dioxide.140 Chitosan’s saccharide degradation products do
not elicit chronic foreign body reactions because of gradual absorbtion by the human body.128 In
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contrast, when chitosan is more crystalline, normally due to high DDA, the chains are closely
packed averting lysozyme interaction which reduces degradation capacity.139 Implementation of
chitosan in a biodegradable local delivery system for antibiotics obviates the need for a removal
surgery, reducing the total cost and trauma to the patient in comparison to other local antibiotic
delivery devices such as polymethylmethacrylate (PMMA) beads.128
Over 200 applications incorporating chitin, chitosan or a derivative are being investigated
or in practice.127, 129 Cosmetics, agriculture, food, biomedical and textile industries are a few
examples of the applications. For medical uses, chitosan may be used as a component of wound
dressings,141, 142 bioactive coatings for orthopaedic and craniofacial implants 58, 143 and drug
delivery systems amongst many others.144-150 Chitosan-based drug delivery systems have been
loaded with several types of drug molecules, including vancomycin146, amikacin149,
gentamicin145, daptomycin149, prednisolone148, rhBMP-2151, rifampin152, ciprofloxacin.153
Chitosan has the ability to rapidly clot blood when partially dehydrated, which enables its usage
as a bandage or hemostatic agent.145 Fully hydrated chitosan contains properties that allows it to
rapidly rehydrate and absorb drugs.141
Biofilm
The formation of biofilm, surface-adhering bacteria, presents challenges that are either
costly or exceptionally difficult to overcome in wound treatment, particularly musculoskeletal
wounds.95 Once the formation of the biofilm is detected effectual eradication has proven to be
arduous. Biofilm treatment hurdles include the direct communication between the bacteria
through the elaboration and recognition of small molecules.154 Staphylococcus aureus and
Pseudomonas aeruginosa bacterial strains have been discovered to be among the most common
culprits in biofilm.74, 94 Various antibiotics that possess high levels of activity against many
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planktonic bacteria have been evaluated against those same bacteria in a biofilm with little to no
success of inhibition. Some studies have demonstrated the ability of several antibiotics to
infiltrate bacteria and prevent further growth, however the most effective classes of those same
antibiotics against biofilm have revealed bacterial recurrence when used singularly.114, 155, 156
Reduction in antibiotic vulnerability in the biofilm bacteria is a key component of the potential
failure to inhibit or the recurrence.155
Biofilm infections that are related to implant devices are problematic because the bacteria
has the ability to adhere and form the biofilm on these foreign materials.91 Microbial
colonization has been implicated as the main causative factor in the pathogenesis of implant
failures.157-159 Treatment of implant related biofilm, if unsuccessful, might require additional
surgeries to remove the infected tissue or implant component.160, 161 Developing a treatment
method that reduces the required removal of implants due to the formation of biofilm is
immensely critical. Patient comfort, costs to patient and/or insurance company (private,
company-sponsored or public) and additional potential complications are all concerns once the
implant-based biofilm requires removal for adequate management.50, 56
Summary
Domestically, infected musculoskeletal wound treatments present challenges that appear
perpetual with as much ongoing research in efforts to combat them. The current methods of
wound debridement, lavage, and fixation are not able to prevent all infections when instigated
solitarily. Infection prevention and wound promotion within the first 72 – 168 hours are crucial
objectives that should be met.32 An increase in antibiotic resistant organisms coupled with the
increasing number of surgical site infections are two rising concerns.43, 45 Rifampin is a viable
candidate for the treatment of Gram-positive and resistant S. aureus when used in conjunction
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with another antibiotic.74, 116, 162-164 Ciprofloxacin has shown some success against Gramnegative bacteria while being investigated for various applications, making it a feasible
aspirant.72, 74, 165, 166 Local delivery of antibiotics with a biodegradable chitosan sponge would be
advantageous for adjunctive musculoskeletal wound treatment. The aim of this research is to (1)
determine if the combination of ciprofloxacin and rifampin is efficacious in inhibiting the
bacteria known to be present in biofilm when delivered from a chitosan-based delivery device,
(2) allow the surgeon or medical provider to load this antibiotic cocktail in situ, and (3) sustain
antibiotic elution and degradation properties to be applicable as a surgically adaptable device
wrap or for wound coverage.
Hypothesis
It is hypothesized that engineered porous chitosan sponges, after being hydrated with
ciprofloxacin and rifampin as a short-term adjunctive treatment, less than 14 days, will be
effective at biofilm-related infection prevention when situated on or around implanted devices or
on traumatic wounds. The sponge will elute antibiotics while biodegrading to inhibit infection,
which may develop into biofilm, thus eliminating surgical need for removal of local delivery
device.
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CHAPTER III
Ciprofloxacin and Rifampin Dual Antibiotic-Loaded Biopolymer Chitosan Sponge for
Bacterial Inhibition
ABSTRACT
Complex extremity wounds in Wounded Warriors can become contaminated with
microbes, which may lead to amputation, morbidity, or even fatality. Local delivery of multiple
or broad-spectrum antibiotics allows practicing clinicians treatment solutions that may inhibit
implant-associated infection. The development of vancomycin-resistant S. aureus (VRSA) has
become a critical challenge in nosocomial infection prevention in the United States. As an
alternative to vancomycin in combination with another antibiotic, locally delivered ciprofloxacin
and rifampin were investigated in a preclinical model for the prevention of biofilm in complex
extremity wounds with implanted fixation device. In vitro assays demonstrated ciprofloxacin and
rifampin possess an additive effect against Gram-negative P. aeruginosa and were actively
eluted from a chitosan sponge based local delivery system. In an in vivo orthopaedic hardwareassociated polymicrobial model (S. aureus and E. coli) the combination could achieve complete
clearance of both bacterial strains. E. coli was detected in bone of untreated animals, but did not
form biofilm on wires. Results reveal the clinical potential of antibiotic-loaded chitosan sponges
to inhibit infection through tailored antibiotic selection at desired concentrations with efficacy
towards biofilm inhibition.
INTRODUCTION
Bone fixation devices may be required to ameliorate traumatic injuries and some
procedures to the musculoskeletal system. According to estimates, open fracture and extremity
trauma are estimated to be six million or more each year in the United States (US).4 Infection

rates of 5% are seen when fixation devices are implemented in musculoskeletal injuries.5
Wound infection remains a major cause of morbidity and mortality in US military Service
members who experience nonfatal combat-related injuries, notwithstanding current innovations
in medical treatment options.167 Wound infection studies of blast injury resulting from combat
operations report several contributing factors, including but not limited to, pathogen, injury type
and severity, study population, infection outcome, and geographic zones. These studies reveal
that US military personnel have combat-related infection rates ranging from 5.5% to 49%.168
Multiple factors may contribute to development of musculoskeletal wound infections, including
but not limited to, traumatic injuries, surgical wounds, delayed definitive treatment method of
acute wounds, or accompanying co-morbidities, which impedes the innate healing process and
patient recovery. Rate of occurrence of bacterial resistance to antibiotics is increasing for
musculoskeletal infections, magnifying an already difficult treatment prospect.6 Socioeconomic
costs have increased due to the contribution of complications resulting from infection.28
Engineered inexpensive biodegradable local delivery devices, loaded with widely available
antibiotics, could be advantageous to prevent infection, especially infections resulting from
biofilm formation on fracture fixation devices. 169-172 More than 65% of infections being treated
in the developed world are caused by biofilm forming bacteria.173
Injuries that result from combat-related blasts possess a high probability of infection due
to the complexity of the wounds and the existence of environmental contaminants, with some
studies showing biofilm forming within a matter of hours after injury.174 Injuries received on the
battlefield are further complicated when Staphylococcus aureus (S. aureus) and Pseudomonas
aeruginosa (P. aeruginosa) are involved. These bacteria are the most prevalent Gram-positive
and Gram-negative pathogens and are attributed with 75% of biofilm infections on medical
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devices.174, 175 Escherichia coli (E. coli) and P. aeruginosa were two of the more frequent
bacterial strains reported during recent military operations, with verified presence in 14% of
wounds.175 Delay of return to duty, an increase in hospitalization associated costs, and/or
permanent incapacitation are sequelae that may result from the treatment of infections.161, 175-177
Infection prevention after an injury is a principal strategy in managing combat-related
trauma, with administration of systemic antibiotics within three hours of injury to reduce the
chance of wound infection and bacterial colonization being the primary care option utilized.174,
176

Local delivery systems for antibiotics, such as antibiotic-loaded poly(methyl methacrylate)

beads (PMMA) and calcium sulfate, are growing in acceptance as an adjunctive approach to
systemic delivery.178-180 Local delivery systems may be advantageous over systemic
administration in that they deliver higher concentrations of antibiotic directly to the affected
tissue178 and minimize risk of toxicity to organs.179, 181-183 PMMA beads are non-degradable and
require an additional surgery to remove the implanted material for complete wound healing.
Additionally, once PMMA beads have released their antibiotic load, they provide surfaces for
potential biofilm formation.184 Rapid resorption of calcium sulfate pellets results in calcium-rich
fluid that incites an inflammatory response and wound drainage.11 The ability to load a local
delivery device with broad spectrum or multiple antibiotics by the attending clinician at the time
of intervention may reduce the incidence of polymicrobial contamination. Local antibiotic
delivery systems should possess the capability for an extended release profile, biocompatibility,
biodegradability with biocompatible degradation products, and personalized antimicrobial
selection depending on the individual and what bacteria are being targeted.185
Chitosan, an adaptable natural biopolymer, has been used to fabricate a myriad of drug
delivery systems,185-187 including lyophilized sponges.188 Commercially available chitosan
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wound dressings in the form of a sponge were approved by the FDA for wound management,
possessing the ability to be hydrated with solutions for applications involving varying degrees of
musculoskeletal wounds. Practicing physicians, at their clinical discretion, may choose to include
antibiotics in the hydrating solution in their treatment solution of contaminated or infected
traumatic injuries.189, 190 FDA clearance of antibiotic introduction into the hydrating solution has
not been specifically obtained in any approved local delivery device including PMMA and
calcium sulfate. Chitosan sponges have shown excellent biocompatibility, degradability, and
may be loaded with countless antibiotics by inert absorption and diffusion.170, 185, 188, 190, 191
Sponge fabrication allows for varying thicknesses and pore sizes using a lyophilization process,
permitting the release of antibiotic solutions to be tailorable,188, 192 with geometry that can be
customized for treatment of complex wounds. This study seeks to investigate the effects of
combining ciprofloxacin (Cipro) and rifampin (Rif) for local delivery from chitosan-based
sponges for infection prevention. In vitro and in vivo tests were used to evaluate the efficacy of
combined therapy of ciprofloxacin and rifampin against pathogens commonly associated with
infection resulting from complex musculoskeletal wounds and/or implants.
MATERIALS AND METHODS
A sample size of 5 allows for detection of a difference of 6 µg mL-1 with an estimated
standard deviation of 2.5 µg mL-1 in elution studies with power 0.80. The analysis was based on
elution data obtained from previous studies conducted within the lab. This sample size was used
throughout the study in all phases, except the in vivo animal model (n = 12) and a preliminary
proof of concept (POC) elution study (n = 4).
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Chitosan Sponges
Chitopharm S chitosan was obtained from Chitinor AS (Tromsø, Norway) having an 82 ±
2 DDA, 251 ± 17 kDa weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity
index, all manufacturer reported values. Poly(ethylene glycol) (PEG) was purchased from Sigma
Aldrich (St. Louis, MO, USA) having a 6 kDa MW.
Sentrex BioSponge®, a chitosan-based approved wound dressing sponge, (Bionova
Medical, Germantown, TN, USA) was included in the study due to its clinical use and
commercial availability.
Chitosan sponges containing 2.0% chitosan or 1.5% chitosan and 0.5% PEG were
fabricated and used in all in vitro studies alongside BioSponge® (Bionova Medical,
Germantown, TN, USA) except for the in vivo implant-associated biofilm model. BioSponge
was the only chitosan sponge used for the in vivo animal model.
Fabricated chitosan sponges, for all in vitro studies, were made by dissolving either 2.0%
chitosan (w/v) or 0.5% poly(ethylene glycol) (PEG) and 1.5% chitosan (w/v) in 1% acidic (v/v)
solutions. 188, 193 The solutions were placed in template containers with the desired shape and
thickness and frozen at -20° C. Once frozen, the sponges were lyophilized, neutralized, frozen
again, lyophilized again and then sterilized (Sterigenics, West Memphis, AR, USA) using low
dose gamma radiation (25 – 40 kGy).
Antibiotic Dissolution
Targeted applications of the studies incorporated to test the efficacy of the Cipro/Rif
combination required that the antibiotics be in solution. The dissolution of rifampin proved to be
the most challenging aspect. Preliminary elution studies failed to address the solubility issue and
the results (not shown) were comparable to prior studies.172, 193 However, it was later shown that
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rifampin’s dissolution was not adequate for our targeted applications. Rifampin and its solubility
was addressed by using 0.1 N hydrochloric acid (HCl) at 37° C with a final pH of 6.02. Scanning
electron microscopy (SEM) images were taken to ensure that the solution pH value did not affect
the structure or integrity of the chitosan sponges (Figs. 1, 2, and 3).

FIGURE 1.SEM images of the BioSponge pre-hydration (top) and post-hydration (bottom).
The sponge was hydrated in antibiotic solution for 10 minutes, which may be comparable
for times in a clinical environment. As shown the pH of the hydrating solution was not
adversely breaking down the structure.
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FIGURE 2. SEM images of the 0.5% Peg/1.5% chitosan sponge pre-hydration (top)
and post-hydration (bottom). The sponge was hydrated in antibiotic solution for 10
minutes, which may be comparable for times in a clinical environment. As shown the
pH of the hydrating solution was not adversely breaking down the structure.
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FIGURE 3. SEM images of the 2.0% chitosan sponge pre-hydration (top) and posthydration (bottom). The sponge was hydrated in antibiotic solution for 10 minutes,
which may be comparable for times in a clinical environment. As shown the pH of the
hydrating solution was not adversely breaking down the structure.

In Vitro Elution
BioSponge, 2.0% chitosan, and 0.5% PEG/1.5% chitosan sponges were sectioned and
weighed to nominal masses of 25 mg. The sponges were loaded with 5mg mL-1 of ciprofloxacin
(Acros Organics, Geel, Belgium) and 5 mg mL-1 of rifampin (Fisher Scientific, Fair Lawn, New
24

Jersey, USA), the solvent was sterile 1X phosphate buffered saline (PBS). Each sponge was
immersed in abundant ciprofloxacin and rifampin antibiotic solution (~10 mL) to allow
hydration saturation. Sponge pre- and post-hydration masses were recorded to calculate
approximate antibiotic solution volume absorbed into the samples. The sponge sections were
gently placed within 125 mL NALGENE® containers with no impedance to natural structure,
which allowed for adequate coverage by solution. Sterile 1X PBS (30 mL) was used to submerge
the antibiotic-hydrated sectioned sponges. The submerged sponges were placed in an incubator
(LabDoctor™ Mini Incubated Shaker, MidSci, St. Louis, MO, USA) at 37° C under constant
motion (30 rpm). Samples of 15 mL each were taken at 1, 2, 3, 4, 5, 6, and 7 days. When the
samples were taken, the PBS solution was refreshed. The samples that required PBS refreshment
were returned to incubator until their time-period was reached, at which point the process
repeated until all time points were elapsed. All sample collection and PBS exchange was
conducted in an aseptic environment. Once samples were collected they were stored for eluate
concentration analysis. Eluate sample storage was at -20 °C to prevent antibiotic degradation and
maintain any active antibiotic activity.
Eluate Concentration Analysis
High-pressure liquid chromatography (HPLC), (UltiMate 3000, Thermo Scientific, West
Palm Beach, FL, USA) was the analytical technique used to quantify the concentration of
antibiotics in the sponge eluates. HPLC analysis for both antibiotics was modeled after a method
used by Liu et al.194 Chromatographic separation was achieved by using a mixture of methanolacetonitrile-dipotassium phosphate (55 mM)-phosphoric acid (1.0M) (28:30:38:4, v/v) as the
primary mobile phase (MP1), in addition to a buffer solution consisting of 55 mM K2HPO4 and
1.0 M H3PO4 (MP2). Ciprofloxacin was read at λ = 280 bandwidth of 4 with a retention time of
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2.38 minutes. Rifampin was read at λ = 333 bandwidth of 4 with a retention time of 11.21
minutes. A gradient method was utilized with at a flow rate of 1.5 mL/min. Detection of
ciprofloxacin occurred with MP2 at 60% and MP1 at 40% the gradient was then ramped up at 3
minutes to 100% MP1 for the detection of rifampin. The concentrations of the antibiotics were
measured to determine their elution profile over time.194-209
In Vitro Antibiotic Activity
The antibiotic activity was completed on two separate occasions due to the solubility
concern.
P. aeruginosa (ATCC 27317) was grown overnight at 37 °C in trypticase soy broth
(TSB). The overnight growth was diluted 1:50 in TSB and 100 µL of this was added to plates of
TSB agar and spread to make a lawn of bacteria. Once the lawn of bacteria was complete 6 mm
blank discs (Beckton, Dickinson cat # 231039) were placed on the agar plates. After the
placement of the disks was the addition of 20 µL of the sponge eluate to the disks. The plates
were incubated for 24 h at 37 °C, pictures were taken and the diameter of the ZOI was recorded.
Each plate contained five replicates for each group and time point. S. aureus (Cowan I ATCC
12598) was grown and tested exactly as P. aeruginosa except for the dilution being 1:10.
In vitro synergy assay
Checkerboard synergy testing was performed using 96-well microtiter plates.
Ciprofloxacin and rifampin were dissolved in phosphate buffered saline (PBS) and diluted in
tryptic soy broth (TSB) in seven 2-fold dilutions from 4 µg mL-1 for ciprofloxacin plated against
P. aeruginosa (ATCC 27317) and from 2 µg mL-1 plated against S. aureus (UAMS-1). Rifampin
concentrations were from 256 µg mL-1 against S. aureus (UAMS-1) and from 0.06 µg mL-1
against P. aeruginosa (ATCC 27317). Each solution was pipetted into triplicate wells of the 96-
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well plate. Positive and negative controls for this experiment were inoculating TSB, without
antibiotics, with and without bacteria, respectively. Each well was inoculated with S. aureus
(UAMS-1) or P. aeruginosa (ATCC 27317) for a final concentration of approximately 1 x 104
CFUs per well. Plates were incubated for 24 hours at 37°C.
Planktonic bacteria were removed from the wells through aspiration of the liquid without
disturbing the biofilm followed by gently washing with PBS three times. Heat fixation of the
biofilm bacteria was achieved by heating the microtiter plate at 60°C for one hour. Once the
biofilm was fixed, it was stained using 100 µL of crystal violet solution. Crystal violet not
absorbed by the biofilm was removed by gently rinsing with water. At that time, a de-staining
solution composed of 7.5% acetic acid, 10% methanol, and water was used to dissolve the
absorbed crystal violet. Absorbance measurements were obtained at λ=540 nm using a plate
reader spectrophotometer (Biotek ELx800, Winooski VT, USA). The minimum biofilm
inhibitory concentration (MBIC) is the concentration of antibiotic required to inhibit the
formation of biofilm.
Relationships between antibiotics was quantified using the fractional inhibitory
concentration index (FICI).210, 211 FICI was determined for each antibiotic as follows, the MBIC
for the antibiotic in combination was divided by the MBIC of each antibiotic alone. The FICI for
each antibiotic was summed to acquire a final FICI value. FICI values < 1 were considered
synergistic, ≥ 1 and < 2 were additive, = 2 were indifferent, and > 2 were antagonistic.
In Vivo Implant-Associated Biofilm Model
All methods were approved and monitored for compliance by the animal use committee
at UAMS and by the Animal Care Use and Review Office (ACURO) at the USAMRMC. A pilot

27

murine model with orthopaedic implant-associated infection212 was adapted to use a
polymicrobial mixture of S. aureus (UAMS-1)213 and E. coli (ATCC 25922).214
In the infected mouse pin model (UAMS – IACUC 3579), sterilized chitosan sponges
were hydrated with antibiotic solutions. The sponges were hydrated with 5 mL of an antibiotic
solution combination of ciprofloxacin and rifampin (10 mg mL-1 each). NIH-Swiss mice
C57BL/6, 8 - 12 weeks old, 16 – 18 grams in weight were anesthetized with Isoflurane and
Avertin (400 - 600 µg g-1) and the adequacy of the anesthesia was confirmed by the toe pinch
reflex and the reaction to light shined into the mice eyes. The left leg was cleaned with povidine
iodine and rinsed with 70% ethanol. An incision was made at the knee; a hole was drilled into
the left distal femur with a 26-gauge syringe needle followed by a 23-gauge syringe needle. A
sterile 1 cm x 600 µm diameter stainless steel Kirschner wire was inoculated with approximately
104 colony forming units (CFUs) of UAMS-1 and 102 CFUs of ATCC 25922 and inserted into
the femur. Placement of the pin within the femur can be seen in Fig. 4.

FIGURE 4. Pictured is an x-ray that shows the
placement of the pin within the left femur. The
arrow points to the point of insertion.
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Chitosan sponges loaded with saline (negative control) or the combination of
ciprofloxacin and rifampin at 10 µg mL-1 each were implanted adjacent to the contaminated
implant (n = 12 per group). After surgical site closure, the mice were returned to their cages,
monitored daily, and any that appeared moribund would be euthanized using CO2. None of the
study participants displayed any moribund attributes during the duration of the study. Animals
were euthanized 7 days after the treatment, the wire implant and any associated femur tissue
were removed for determination of viable bacterial CFUs remaining on/in each. The soft tissue
was dissected from the bone and the femur was cut into small pieces, homogenized, and placed
in a sterile saline. Wire implants were sonicated and vortexed in sterile PBS. After overnight
incubation at 37° C, the homogenates were diluted, plated on agar plates, and the viable
microbial colonies were counted along with the colonies remaining on the pin and bone.
Bacterial clearance was defined as an apparent bacterial CFU count of zero.
Statistical Analysis
Statistical analysis of results was performed using Sigma Plot (Systat Software, Inc., San
Jose, CA, USA). One way Kruskal Wallis Analysis of Variance (ANOVA) was used to
determine differences between CFUs retrieved from implants, with p values of < 0.05 being
considered statistically significant. Dunn’s post hoc analysis was used to compare groups
pairwise and determine p values. Fisher exact tests of contingency tables was used to compare
the rate of clearance for implants in antibiotic-loaded groups to controls, with Bonferroni post
hoc correction in cases of multiple comparisons. No other statistical analysis was performed as
the principal purpose of the study was not the comparison of the various sponge types.
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RESULTS
In Vitro Elution
Results from the elution study showed that rifampin elutes, virtually 100%, from its
delivery device within three days (Fig. 5). Ciprofloxacin’s elution profile while still displaying a
burst effect was sustained throughout the duration of the study (Fig. 6).

FIGURE 5. Bar graph of the mean ± standard deviation of rifampin concentration in
sponge eluates (n = 5) over 7 days.
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FIGURE 6. Bar graph of the mean ± standard deviation of ciprofloxacin concentration in
sponge eluates (n = 5) over 7 days.

In vitro antibiotic activity
Eluates from chitosan-based local delivery devices could inhibit P. aeruginosa (ATCC
27317) (Fig. 7) and S. aureus (Cowan I ATCC 12598) (Fig. 8) through the duration of the sevenday study when solubility was addressed. Chitosan sponge eluates from proof-of-concept (POC)
elution could inhibit, on average four days, P. aeruginosa (ATCC 27317) (Fig. 7) and S. aureus
(Cowan I ATCC 12598) (Fig. 8).
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FIGURE 7. Zone of inhibition (ZOI) results of sponge eluates tested against P. aeruginosa (ATCC
27317). On the left of each sponge group were the results before the solubility issue was addressed.
The plates on the right were achieved as the solubility of rifampin was actively addressed.
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FIGURE 8. Zone of inhibition (ZOI) results of sponge eluates tested against S. aureus (Cowan I
ATCC 12598). On the left of each sponge group were the results before the solubility issue was
addressed. The plates on the right were achieved as the solubility of rifampin was actively addressed.

In Vitro Synergy Assay
Results from the synergy assay showed an additive effect between ciprofloxacin and
rifampin against P. aeruginosa (ATCC 27317) with a FICI value of 1 (Table 1) and no
discernible effect against S. aureus (UAMS-1) (Table 1).
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In Vivo Implant-Associated Biofilm Model
The combination of ciprofloxacin and rifampin could completely clear both the pin (Fig.
9) and the bone (Fig. 10) of S. aureus CFUs at seven days. S. aureus clearance can be seen with
SEM images (Fig. 11). While some E. coli colonies were retrieved from the bone tissue in
negative saline controls without loaded antibiotics (Fig. 12), there were no viable colonies after
seven days on the implant (Fig. 13).

FIGURE 9. Dot plot of each animal’s remaining CFUs after implant retrieval. Black
dot and bar represent mean ± standard deviation for the group.
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FIGURE 10. Dot plot of each animal’s remaining CFUs after implant retrieval.
Black dot and bar represent mean ± standard deviation for the group.
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FIGURE 11. SEM image taken of the pin for a PBS pin with no antibiotic loading (top) with a
discernible presence of S. aureus. Ciprofloxacin and rifampin treated pin (bottom).
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FIGURE 12. Dot plot of each animal’s remaining CFUs after implant retrieval. Black
dot and bar represent mean ± standard deviation for the group.

37

FIGURE 13. Dot plot of each animal’s remaining CFUs after implant retrieval. Black
dot represents mean for the group.

DISCUSSION
The primary purpose of this study was to ascertain if dual antibiotic local drug delivery
from chitosan sponges could assist with inhibiting biofilm formation. During the study
antibiotics were actively released from chitosan sponges at levels that were shown to be
inhibitory. This study exhibits that this antibiotic combination may be introduced into a local
delivery system to release active concentrations for infection inhibition. The study results also
suggest a potential additive relationship against Gram-negative P. aeruginosa for ciprofloxacin
and rifampin. Gram-negative bacteria, specifically P. aeruginosa, has a history of being
persistent,188, 190 treatment options consisting of antibiotics with different mechanisms of action
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that are additive may eliminate the persister bacterial cells in potential clinical applications. No
discernible effects, synergistic, additive, antagonistic, or indifferent, were obtained against the
Gram-positive S. aureus due to the combination completely inhibiting the growth. While the
ability to inhibit biofilm was not determined by the in vitro synergy assay it was shown that this
combination can inhibit S. aureus growth. The efficacy of this treatment method was further
investigated using a known model of implant infection. Results revealed complete clearance of
Gram-positive S. aureus when dual-loaded chitosan sponges were introduced. The combination
of ciprofloxacin and rifampin performance under physiological conditions, which are difficult to
simulate in vitro, offers more validation that the combination may be a potential treatment option
for practicing physicians.
The combination of ciprofloxacin and rifampin may provide improved treatment for
infection prevention in musculoskeletal wounds and/or injuries. Ciprofloxacin is a 2nd
generation fluoroquinolone that has been clinically effective at inhibiting some bacteria.67-76
Quinolones/fluoroquinolones have proven to be effective against bacteria due to their ability to
prevent the DNA from unwinding and duplicating.60 Ciprofloxacin is one of the numerous
fluoroquinolones that have extensive clinical usage for the treatment of Gram-negative and some
Gram-positive bacterial pathogens.63, 65, 66, 78-83 Rifampin has emerged as a major player in
antibiotic combination therapy to combat biofilm among other infections. Rifamycins,
represented by rifampin, specifically inhibits bacterial DNA-dependent RNA polymerase by
blocking the RNA chain initiation step of bacterial DNA transcription to messenger RNA that is
needed to synthesize bacterial proteins.97,62 Rifampin is bactericidal against Gram-positive
bacteria and diffuses well into biofilm where it perpetuates it bactericidal ability.62 Disruption of
biofilm is within the scope of rifampin, however rifampin-resistant mutants may be selected.62
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Rifampin requires to be used in conjunction with other antibiotics as a result.62 Rifampin has
been tested with a number of other antibiotics for potential synergistic effects against
Acinetobacter baumannii,3 Klebsiella pneumoniae,215 and S. aureus216 among others.
Ciprofloxacin has been investigated in conjunction with several antibiotics against P.
aeruginosa3, Enterbacteriaceae and D. streptococcal8 to name a few. Very few studies have
reported the effects of the combination of ciprofloxacin and rifampin against the strains of
bacteria tested here. In a study by Zimmerli et al., a cure rate of 100% was achieved for those in
the ciprofloxacin-rifampin group in patients with culture-proven Staphylococcal infection
associated with stable orthopedic implants.164 Ciprofloxacin and rifampin was the most effective
treatment regimen in reduction of MRSA in bone in rats with experimental osteomyelitis.217 The
groups tested were vancomycin, vancomycin-rifampin, ciprofloxacin, ciprofloxacin-rifampin,
rifampin, and a control group.217 Widmer et al. concluded that combination therapy with
rifampin and a quinolone should be considered for patients with orthopedic implant-related
infections if the implant cannot be removed.218 The Widmer study centered around patients with
infections resulting from staphylococci or streptococci.218
The additive effect against P. aeruginosa shows promise for this combination. Complete
inhibition of S. aureus was validated with results from most phases of the study with culmination
coming from the implant-associated biofilm model. Biofilm synergy assay results for S. aureus
were not able to be determined as the concentrations of the antibiotics completely inhibited
growth. Future investigations are planned with lower concentrations of both antibiotics. There
have been recent studies that were shown to completely clear P. aeruginosa and S. aureus on
implants through systems consisting of phospholipid coatings impregnated with amikacin and
vancomycin219 or injectable hydrogels containing high doses of gentamicin220, respectively. One
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of the main disadvantages of chitosan sponge based local delivery systems is their dependence
upon diffusion, which may result in not all aspects of an implant receiving antibiotics above the
MBIC.23, 27 Sponges have an advantage of being loaded with a customizable treatment solution
immediately prior to application. Sponges do not require prefabrication in comparison with
coatings or hydrogels, giving them practibility for quick interventions as needed, whether in the
field or on the surgical table.220, 221 These results extended those previously obtained that
demonstrate biofilm inhibition in soft tissue implant-associated models170 providing credence to
activity in prevention of bone infection.
One major limitation for this study revolved around the in vivo model. This resulted from
the strain of E. coli (ATCC 25922) used, which was not robust nor readily form biofilms. The
method was adapted from an osteomyelitis model of which the investigators reported issues with
the use of this specific strain.214 In efforts to reduce or prevent severe morbidity and mortality
that have previously occurred in polymicrobial models containing S. aureus and P.
aeruginosa,170 E. coli was selected. Lack of the robust biofilm formation greatly limits our
ability to generalize conclusions to polymicrobial infections. Future in vivo investigations of
polymicrobial biofilm will be modeled to include a more pathogenic, biofilm-forming Gramnegative bacteria, such as P. aeruginosa with an appropriate inoculum adaptation,174, 222, 223 with
groups receiving no local delivery of antibiotics receiving systemic delivery.
CONCLUSIONS
The ability of ciprofloxacin and rifampin, in combination, to inhibit S. aureus and P.
aeruginosa growth in an in vitro environment and S. aureus and E. coli when released from
chitosan sponges in vivo illustrates the clinical potential of this local delivery approach for
infection prevention in extremity trauma. Complete clearance or inhibition of contaminating
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biofilm pathogens may be achieved with the implementation of these antibiotics loaded within
chitosan sponges.
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CHAPTER IV
DISCUSSION
Biofilm can further complicate musculoskeletal wounds normally increasing treatment time,
costs, patient morbidity, and required surgeries.1, 2, 215, 216 Antibiotic dosages that may be adverse to
the patient are required to clear localized bacteria when administered systemically due to common
vascular compromise in musculoskeletal wounds.3, 8 Chitosan local delivery devices and their
development were in response to a clinical need for local delivery devices there are efficacious in
clearance of bacteria, biocompatible, completely biodegradable, and allow tailored point-of-care
loading.171, 188, 191, 224 Throughout the overall study these aspects were investigated to ensure that the
chitosan-based local delivery systems tested actually fulfilled these requirements. Whereas, these
secondary investigations were not directly related to the hypothesis however, they support a primary
aspect of this research.
Multiple variations of chitosan sponges in parallel with a commercially available chitosan
sponge were tested during the proof of principle phase. This was done to determine which variation
would be most functional throughout the duration of the overall study. Table 1 in Appendix A
displays all variations and their composition. Zone of inhibition (ZOI) sponge eluate activity results
are displayed in Appendix B. Based on the results, it appears that the chitosan content affects the
duration of the sponge eluate at bacterial inhibition. During this phase activity lasted on average
through three days, which could be clinically relevant if all present bacteria was 100% eradicated.
However, if some bacteria remain after the three days it could lead to the formation of persister cells
and could result in antibiotic resistance. Parker et al. reported an initial burst release of loaded
vancomycin from neutral chitosan/PEG and chitosan sponges after one hour, experiencing a
significant decrease in eluted antibiotic thereafter.224 An investigation by Noel et al. of in vitro
release properties of vancomycin from chitosan sponges fabricated with lactic and acetic acid showed

an initial burst release of loaded vancomycin after one hour, while also experiencing a significant
decrease in eluted antibiotic thereafter.190 As demonstrated in Chapter III, sponge eluate activity
could be extended throughout seven days adding credence to the use of rifampin and ciprofloxacin in
a clinical application for bacterial inhibition, while Noel et al. found that virtually all of the loaded
vancomycin was released after 72 hours.190 Vancomycin concentrations found by Parker et al. were
above the MIC through 24 hours, eluates utilized for turbidity testing only remained active against S.
aureus through six hours.224 Noel et al. found that the levels of 32 vancomycin eluates remained
above the MIC active through 72 hours.190 Noel et al. also reported amikacin eluates from chitosan
sponges remaining active through 48 hours.190 Turbidity testing performed on ciprofloxacin and
rifampin loaded sponge eluates during the preliminary proof-of-principle study were active through
three days. Additionally, the prior studies by Parker et al. and Noel et al. were single-loaded in
comparison with the dual-loaded implemented for this study. An additional test for sponge eluate
activity was conducted and its result can be seen in Appendix C. The turbidity test was conducted in
parallel to the ZOI test to validate the procedure. Turbidity results confirmed what was seen with the
ZOI results. Due to potential inaccurate readings, because of rifampin’s color turbidity testing may
not be advantageous. Rifampin, when properly in solution, will have an orange color, which could
affect the absorbance, which is what is measured in turbidity.

Degradation of any local delivery device is advantageous over delivery systems that do
not degrade. One of the more prevalent local delivery mechanisms practicing clinicians employ
is PMMA beads, which maintain a steady stable elution profile. Some drawbacks of PMMA
beads include, but are not limited to, lack of degradation and introduction of addition surface
area into the surgical site or wound bed for bacterial attachment. Chitosan sponges possess the
ability to biodegrade with no adverse byproducts. To confirm this two experimental degradation
methods were used during the study on chitosan sponges, enzymatic and oxidative.171 As seen in
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Appendix D (Figure 19), enzymatic degradation with lysozyme was minimal whereas oxidative
degradation was more robust (Figure 18) and useful in ranking degradation rates/amounts of different
local delivery constructs. Oxidative testing is gaining more uses and its physiological representation
is still being determined for chitosan-based systems.171 Chitosan degradation by lysozyme has been
established but to truly understand degradation of chitosan in vivo implantation is required and can be
determined using histological methods.171
Chitosan sponges should be able to accept the required amounts of any tailored antimicrobial
point-of-care loading necessary for desired treatment. This functional need was investigated by
subjecting the chitosan sponges to a swelling ratio test. All tested sponges returned the ability to be
loaded at >1000% with an aqueous solution of their initial mass, Appendix D (Table 4). Chitosan
sponges possessing the ability to absorb more than 10 times their mass makes them good candidates
for short-term local delivery treatment options.
Biocompatibility evaluation was conducted and reported in Chapter III but in vitro tests of
cytocompatibility of the chitosan sponges were conducted prior and the results are seen in Appendix
F. BioSponge had the highest cytocompatibility of the tested sponges at 24 and 72 hours (Figures 21
& 22). This positive outcome was expected since this product has been tested extensively by Bionova
Medical and approved to be marketed as a wound dressing by the Food and Drug Administration
(FDA). Study results revealed that the least cytocompatible of the tested chitosan sponges was the

2.0% chitosan sponge. There was more deviation seen in the 24-hour results compared with 72hour. BioSponge cell proliferation exceeded the control (TCP empty well), which had no contact
with any sponge. This cell number increase from this evaluation introduces the possibility that
BioSponge may promote cell growth. More precise evaluations on cell function are needed for a
more complete determination because cell culture does not truly duplicate the conditions and the
whole story of in vivo compatibility. Standard deviation in the 1.5% chitosan sponges could
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negate that fact that it exceeded the control at both designated times. For the 72-hour study,
every sponge exceeded the control. Viable cell numbers decreased at 72-hours for BioSponge
and 1.5% chitosan/0.5% PEG but increased for the 2.0% chitosan sponge in comparison to 24hours results. This result could have come from improper loading/seeding techniques or the
loading of the sponges into the wells during 24-hour study. Another possible factor could be that
the cells needed time to adapt to the sponges. A longer study will be suggested for future
experimentation.
Study limitations include the murine size, which has a small defect size and may not be
physiologically representative of infected, complex, and large wounds in a clinical setting. Sections
of the sponges were tested due to limitations in the animal wound size and in available testing
parameters. Results may or may not be indicative of testing the complete sponge structure in a large
complex musculoskeletal wound. However, the practicing clinician has the ability and may choose to
re-size the chitosan sponge for the desired treatment plan. All in vitro studies were performed under
controlled conditions, which may not directly correlate to in vivo performance. Ciprofloxacin and
rifampin were tested together and not separately. This dual antibiotic use was selected and completed
due to the previously reported issue that rifampin must be used in combination with another
antibiotic. Most in vitro studies were performed during a reduced time-frame and all tested sponges
during in vitro testing except for elution and porosity did not include the antibiotics.
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CHAPTER V
CONCLUSIONS
This body of work and the studies performed within it support inclusion of ciprofloxacin and
rifampin as a treatment option when loaded as a point-of-care solution. The chitosan sponge eluates
showed activity through seven days which support our use as a short-term treatment option. Through
local and short-term use the treatment cocktail avoids the recent released literature and FDA reports
of adverse effects resulting from systemic use of ciprofloxacin. Ciprofloxacin based on results
complements rifampin, which was released completely at three days in similar fashion to prior
studies.
In vitro biofilm assay study results were inconclusive against S. aureus due to the
combination completely inhibiting growth at the concentrations tested. Biofilm disruption was seen
against P. aeruginosa offering support of the reported claim and selection of rifampin for this
research. Further testing is needed at reduced concentrations, at minimum 3-fold below reported MIC
values, to obtain viable results against S. aureus. Solubility of rifampin appeared to be temperature
dependent, however contingent on specific application and treatment plan solubility may not be an
issue. Recent unpublished ongoing studies are introducing powder rifampin in vivo, like the common
vancomycin “sprinkle” and allowing physiological processes to solubilize. This proposed local
delivery system required all antibiotics solubilized to load a desired concentration in the chitosan
sponge. This study determined a method that allowed this to be accomplished without affecting the
structure of the chitosan sponge in a detrimental way.
Rifampin and ciprofloxacin cleared all bacteria in the in vivo functional murine model with
no adverse effects to the mice. Although the results were not without a caveat as the biofilm-forming
E. coli strain cleared was not robust. Future testing with a more robust Gram-negative bacterium, like
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biofilm-forming P. aeruginosa, would be required to confirm activity against polymicrobial
infection.
In conclusion, a system that affords drug loading and tailored release to individual patient
need and surgeon preference is advantageous in infection inhibition. The results presented in this
body of work provide validation of the stated hypothesis: that engineered porous chitosan sponges,

after being hydrated with ciprofloxacin and rifampin for short-term treatment, less than 14 days,
would be effective at biofilm-related infection prevention. More in vivo testing is needed, as with
most proposed treatment solutions, to confirm many of the reported conclusions, i.e. degradation,
biofilm effects. With additional research the ciprofloxacin/rifampin combination may prove to be
a viable option for local treatment amalgamation with standard surgical treatment of complex
musculoskeletal injuries in infection prevention and biofilm-related infection prevention of
surgical site infections.
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CHAPTER VI
FUTURE WORK
To validate the efficacy of ciprofloxacin and rifampin when released from chitosan-based and
other proven local delivery devices further in vitro and in vivo research must be conducted.
Ciprofloxacin and rifampin should be investigated monogamously for elution and activity to
determine if one effects the other. Solubility of rifampin with simply temperature (37° C) as a
catalyst should be investigated, which may provide an easier method for complete dissolution.
Investigation of pore size and structure when the chitosan sponge is singularly loaded is worth
pursuing for many of the same reasons previously stated. While bacterial inhibition was the primary
endpoint of the functional murine infected pin model, investigation of an established bacterial
infection should be assessed during future studies. The functional infected pin model simulated metal
hardware, a complement would be a functional model that simulates infected polymer implants.
Although no adverse effects were seen at the antibiotic concentration used during the functional
murine model future studies should address what concentrations are required for inhibition of each
and proceed at those values.
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APPENDIX A: DETAILED MATERIALS AND METHODS FOR CHAPTER III
Chitosan Sponge Fabrication
Fisher Scientific (Pittsburg, PA, USA) supplied all materials unless noted. The 1.5%
chitosan/0.5% PEG sponge fabrication consisted of Chitopharm S chitosan powder (Chitnor AS,
Tromsø, Norway) with an 82 ± 2 DDA, 251 ± 17 kDa weight-average molecular weight (MW)
and 2.013 ± 0.145 polydispersity index and polyethylene glycol (PEG) with a molecular weight
of 6000 g mol-1 (Sigma Aldrich, St. Louis, MO, USA). The 2.0% chitosan sponge consisted of
only Chitopharm S chitosan powder. Bionova Medical (Germantown, TN, USA) provided
commercially available sterile BioSponge with proprietary composition. For the chitosan/PEG
sponge 1% acidic acid v/v dissolved 0.5% PEG w/v in ultrapure water, additional chitosan/PEG
sponges with varying chitosan content were fabricated in same manner (Table 1). The solution
then dissolved 1.5% chitosan after complete dissolution of the PEG. An acid mixture of 0.75%
lactic acid v/v and 0.25% acidic acid v/v dissolved 2.0% w/v chitosan in ultrapure water to make
the 2.0% chitosan sponge, additional chitosan sponges with varying chitosan content were
fabricated with same procedure (Table 1). Once complete dissolution was achieved 250 mL
aliquots of the solutions were cast in 4 x 8 cm containers and frozen overnight at -20° C.
Benchtop freeze dryers (LabConco, Kansas City, MO, USA) lyophilized the frozen solutions
after they were removed from the freezer creating acidic dehydrated sponges. Sodium hydroxide
(NaOH) solutions of 600 mM and 250 mM assisted in the neutralization of the acidic chitosan
and chitosan/PEG sponges, respectively. Sponges were covered in the appropriate NaOH
solution for approximately seven minutes. At the expiration of the seven minutes the NaOH
solution was removed and the sponges were washed with ultrapure water until their eluate tested
for a neutral pH. Neutral sponges were then frozen again at -20° C for one hour and lyophilized
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to create the neutral unsterilized sponges. Sterigenics (West Memphis, AR, USA) sterilized all
fabricated twice lyophilized neutral using low dose gamma radiation (25 – 40 kGy).
Table 1. Composition of various chitosan sponges used during proof of principle phase of study.
Chitosan Content
Peg Content
Acid Content
Document Reference
1%
N/A
1% (0.75% LA, 0.25% AA)
1C
1.5%
N/A
1% (0.75% LA, 0.25% AA)
1.5C
2%
N/A
1% (0.75% LA, 0.25% AA)
2C
0.5%
0.5%
1% AA
PC
1.0%
0.5%
1% AA
1PC
1.5%
0.5%
1% AA
1.5PC
BioSponge (proprietary content)
B
*Poly(ethylene glycol) (PEG), Acetic Acid (AA), Lactic Acid (LA)

Antibiotic Dissolution
Rifampin (Fisher Scientific, Fair Lawn, New Jersey, USA) and ciprofloxacin·HCl (Acros
Organics, Geel, Belgium) were weighed out, independently, to make 5 mg mL-1 solutions in
ultrapure water. A 0.1 N HCl solution (25° C) was prepared in ultrapure water and 100 mL was
added to a beaker. The temperature was raised to 37° C, rifampin, and 100 mL of ultrapure was
added, temperature was brought to 37° C. If any rifampin was not completely in solution drops
of 0.1 N HCl was added at 37° C until complete dissolution was achieved. Once complete
dissolution of rifampin occurred, the measured amount of ciprofloxacin was added to the
solution and the pH was recorded. A solution of 500 mM NaOH (25° C) in ultrapure water was
prepared. Drops of the NaOH were added to the solution to increase the pH to an acceptable
range that would not affect the chitosan sponge structure. The final pH of the antibiotic solution
at 37° C was 5.86. Attempts to increase the pH above 5.86 resulted in antibiotics falling out of
solution. The solution was transferred to an appropriate volumetric flask and ultrapure water was
added to complete the solution.
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In vitro elution
All procedures contained within this section were conducted within an aseptic
environment. All sterilized sponges were sectioned to and weighed to nominal masses of 25 mg.
Dehydrated sectioned sponges (n = 5) were separately placed in containers with ~10 mL of the 5
mg mL-1 ciprofloxacin/rifampin antibiotic solution for 10 minutes. Sponges were carefully
removed from the container and gently placed in 125 mL NALGENE containers, which had
adequate space for the sponges to keep their natural structure. The mass of the newly antibiotic
hydrated sponges was recorded.
Sterile 1X phosphate buffered saline (PBS) was made from 10X PBS, with ultrapure
water and a Sterilmatic autoclave (Market Forge, Boston, MA, USA). Sterile 1X PBS (30 mL)
was placed in each container, which fully submerged the sponge. Containers were then placed in
an incubator (LabDoctor Mini Incubated Shaker, MidSci, St. Louis, MO, USA) at 37° C under
constant motion of 30 rpm. At predetermined time intervals of 1 – 7 days, systems were removed
daily from the incubator and samples of 10 mL, in 2 mL aliquots, were taken. Systems that were
slated for the day of sample were discarded. Systems that were not slated for the day of sample,
had an aspirator remove the excess fluid, PBS was restored, and the systems were placed back
into the incubator at the same conditions as previously stated. This process continued until day
seven at which point all systems had been properly sampled and discarded. Eluates were stored
immediately after collection in a freezer at -20° C until further analysis.
Eluate Concentration Analysis
High-performance liquid chromatography (UltiMate 3000, Thermo Scientific, West Palm
Beach, FL, USA), formerly known as high-pressure liquid chromatography, determined the
concentration of ciprofloxacin and rifampin in the sponge eluates. Stock concentrations of 1 mg
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mL-1 were made for ciprofloxacin and rifampin for the standard curve and to randomly verify
detection method throughout the sequence. HPLC grade methanol (30%), HPLC grade
acetonitrile (28%), 55 mM dipotassium phosphate (38%), and 1.0 M phosphoric acid were
combined to create the primary mobile phase (MP1). The primary mobile phase implemented to
detect both ciprofloxacin and rifampin was modeled after Liu et al.194 Detection of both
antibiotics with one primary mobile phase required an additional buffer solution (MP2) which
consisted of 1.0 M phosphoric acid and 55 mM dipotassium phosphate. The UltiMate 3000 has
four pumps which made this adaptation possible. MP1 was placed on one pump and MP2 was
fed through another pump.
To ensure MP1 accurately detected targeted antibiotics 1.5 mL of stock concentrations
were placed in 2 mL HPLC vials and analyzed. Now only MP1 was used to detect the targeted
antibiotic ciprofloxacin or rifampin. Once UV-Vis detection, using 2 µL injections, of each (n =
10) was validated by same retention time, height, and sharpness of peak, a gradient method
needed to be optimized to detect both analytes in each sample with one pass. This is necessary if
the retention time of the antibiotics are close enough to introduce potential interference, possibly
skewing results. The adapted MP1’s primary use was detection of rifampin therefore the focus
was on ciprofloxacin. Optimization required adjusting the amount of MP1 and MP2 to
percentages that efficaciously detected ciprofloxacin. After numerous iterations, the final
percentage that detected ciprofloxacin was 60% MP2 and 40% MP1. The new detection
parameter required validation for detection of both ciprofloxacin and rifampin. A new stock
concentration (1.5 mL) that consisted of 1 mg mL-1 ciprofloxacin and 1 mg mL-1 rifampin was
placed into 2 mL HPLC vial for analysis. For efficacious analysis of sponge eluates, a gradient
method needed optimization. To accomplish this all the previously mentioned stock
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concentrations were implemented. The chromatographic separation detection gradient method
required numerous iterations before determining one that returned the desired detection
parameters. The gradient method determined for this analysis consisted of a four-minute
equilibration to ensure 40% PM1 and 60% PM2 at which point the injection was initiated. This
was held steady through three minutes at which point the gradient was ramped up to 100% PM1
and held there for the duration (12 minutes) of the method. Validation of said gradient method
required detection of ciprofloxacin and rifampin from either of the vials in a succession of 25.
The flow rate was 1.5 mL min-1 with a BDS HYPERSIL C18 reverse phase column (Thermo
Scientific, West Palm Beach, FL, USA), held at 30° C set by the method and possible due to the
UltiMate 3000. Ciprofloxacin was read at λ = 280 with a bandwidth of 4 and a retention time of
2.38 minutes. Rifampin was read at λ = 333 with a bandwidth of 4 and a retention time of 11.21
minutes. Sponge eluate samples were thawed and were plated in a 96-well plate (250 µL). Each
96-well plate contained two columns of known concentrations for continued method validation
throughout the sequence. Preliminary proof of principle results are displayed in Figures 14 & 15.

69

Preliminary Results

FIGURE 14. Bar graph of mean ± standard deviation of ciprofloxacin concentration
in sponge eluates (n = 4) during preliminary testing.
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FIGURE 15. Bar graph of mean ± standard deviation of rifampin concentration in
sponge eluates (n = 4) during preliminary testing.

Scanning Electron Microscope Image Acquisition (Sponge Pore Structure)
The dehydrated sponges (n = 4) were sectioned to 6.25 cm2 with half remaining
dehydrated and others loaded with the ciprofloxacin/rifampin antibiotic cocktail (pH 5.86).
Samples were loaded independently for 10 minutes with excess solution removed by aspiration.
Sponge samples needed to be further reduced in size for imaging purposes using a Nova Nano
scanning electron microscope (SEM) 650 Field Emission System. Liquid nitrogen was
implemented to flash freeze the samples allowing for smaller pieces to be cracked from them
with tweezers. The samples were placed in a dewar and placed in liquid nitrogen until frozen.
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Pore structure inside the sponge, which would have been harmed by cutting, was preserved using
this method. Once the samples were of appropriate size, they were attached to SEM sample
holders using double-sided carbon tape and dried in a vacuum oven (21 inHg) for 72 hours at 40°
C. Immediately prior to imaging, samples were coated with a 10 nm layer thick of goldpalladium. Surface area and cross sectional images were taken with an excitation voltage of
15.00 kilovolts at magnifications of 200x.
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APPENDIX B: ZONE OF INHIBTION PHOTOGRAPHS
Pseudomonas aeruginosa

FIGURE 16. Zone of inhibition photographs from the initial preliminary proof of principle elution study testing against P.
aeruginosa.
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Staphylococcus aureus

FIGURE 17. Zone of inhibition photographs from the initial preliminary proof of principle elution study testing against S.
aureus.
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APPENDIX C: CHITOSAN SPONGE ELUATE TURBIDITY
Rationale
Bacteria reside in vivo within an aqueous environment. Blood and other aqueous
solutions provide transport possibilities of bacteria from one location to another.170, 188, 193
Turbidity testing is a pseudo model of this clinical scenario. Eluate samples are tested against
bacteria floating in an aqueous environment to determine whether the treatment can inhibit
growth within solution.
Pseudomonas aeruginosa Turbidity
P. aeruginosa (Schroeter) Migula ATCC 47085, commonly referred to as PAO-1, was
the bacterial strain used during this testing process. The bacterium was diluted 1:50 in TSB and
grown overnight in an incubator at 37 °C. The eluate sample (200 µL) was placed into a 5 mL
polystyrene round-bottom tube (Falcon) with 1.75 mL TSB, and 50 µL PAO-1. Positive controls
consisted of 1.95 mL TSB and 50 µL PAO-1, while negative controls contained 1.8 mL TSB and
200 µL eluate sample. The tubes containing the mixtures was placed in an incubator at 37 °C for
24 h. Once the 24 h were passed the tubes were removed from the incubator and absorbance was
read at λ = 540 on a Spectronic 200 (Thermo Scientific, Waltham, MA, USA). The results can be
seen in Table 2.
Staphylococcus aureus Turbidity
S. aureus ATCC 49230 (osteomyelitis clinical isolate), often referred to as UAMS-1, was
the bacterial strain used during this testing procedure due to its confirmed contribution to bone
infections, being cultured from osteomyelitis. The bacterium was diluted 1:5 in TSB and grown
overnight in an incubator at 37 °C. The eluate sample (200 µL) was placed into a 5 mL
polystyrene round-bottom tube (Falcon) with 1.75 mL TSB, and 50 µL UAMS-1. Positive
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control consisted of 1.95 mL TSB and 50 µL UAMS-1, while negative controls contained 1.8
mL TSB and 200 µL eluate sample. The tubes containing the mixtures were placed in an
incubator at 37 °C for 24 h. After the 24 h had passed the tubes were removed from the incubator
and absorbance was read at λ = 540 nm on a Spectronic 200. The results can be viewed in Table
3.
Results
The results were in agreeance with the ZOI results seen in Appendix B. During this phase
of the investigation no efforts were made to address the solubility of either antibiotic. The results
were still comparable to other previous tested antibiotic combinations and their eluates from
chitosan sponges.
Table 2. Results of turbidity testing for Pseudomonas aeruginosa, (-) indicates inhibition and (+)
indicates growth.

Day
1
2
3
4
5
6
7

0.5% Peg
1.5% Chitosan
+
+
+
+

2.0% Chitosan

BioSponge

+
+
+
+

+
+

Table 3. Results of turbidity testing for Staphylococcus aureus, (-) indicates inhibition and (+) indicates
growth.

Day
1
2
3
4
5
6
7

0.5% Peg
1.5% Chitosan
+
+
+
+
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2.0% Chitosan

BioSponge

+
+
+

+
+
+

APPENDIX D: CHITOSAN SPONGE DEGRADATION
Rationale
Degradability of chitosan sponges is an proposed advantage in clinical applications.171,
172, 225-227

For the purpose of this study, degradation timing shortly after functional elution

completion would be optimal. Degradability was ascertained using two methods, enzymatic and
oxidative.135, 172, 188, 226, 228-234 For both degradation studies sponges were be fabricated and
sectioned as they were for the elution study and SEM imaging (APPENDIX A). Oxidative
accelerated in vitro degradation aids in the determination of overall degradation of the sponge
types for further characterization of longer term in vivo degradation in reduced time frames and
was investigated as a result.235-238 In vitro enzymatic degradation testing with lysozyme has been
established as a physiological representation of in vivo degradation.135, 239-242
Oxidative Degradation
Sponges used for this phase of testing were fabricated or obtained as detailed in
Appendix A. Sectioned sponge masses were recorded. Sponges were hydrated and had in vitro
oxidative degradation evaluated in bacteriological petri dishes 100 x 15 mm (Falcon, Corning,
NY, USA). The samples were hydrated for 10 minutes in 20 mL sterile 1X PBS; excess solution
was removed by aspiration. Once the sponges were hydrated they were submerged in 30 mL of
solution consisting of 1x sterile PBS, 3% H2O2, and 0.1 M CoCl2. Upon submersion, samples
were placed at 37 °C in the LabDoctor Mini. Samples were collected at 3.6, 7.2, 10.8, 14.4 and
18 hours from the beginning of the study. Since this degradation method is accelerated the time
points (18 hours ÷ 5) were adjusted to mimic (ten days sampled every two days) those needed for
enzymatic degradation with lysozyme. Solution was refreshed at all collection intervals.
Collected samples were placed in an oven at 80 °C and allowed to thoroughly dry. When dried,
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the mass of the sponges was measured and recorded. Oxidative sponge mass percent remaining
can be viewed in Figure 18.
Enzymatic Degradation
Sponges used for this phase of testing were fabricated or obtained as detailed in
Appendix A. Sample sponges (n = 4) were sectioned to 9 cm2. Sectioned sponge masses were
recorded. Sponges were hydrated and had in vitro enzymatic degradation evaluated in Falcon
bacteriological petri dishes 100 x 15 mm. The samples were hydrated for 10 minutes in 20 mL
sterile 1x PBS; excess solution was removed by aspiration. Once the sponges were hydrated they
were submerged in a 30 mL of solution consisting of 1x sterile PBS, 1 mg mL-1 lysozyme, and
1% antibiotic/antimycotic (AB/AM), containing penicillin, streptomycin, and amphotericin B.
After submersion, the sponges were placed in the LabDoctor Mini at 37° C. The samples were
collected every two days for duration of study (10 days). When samples were collected all
PBS/lysozyme solution was refreshed in uncollected samples. Uncollected samples were
returned to incubator until the next sample collection time was attained, at which time the
process repeated until all predetermined time points were achieved. Collected samples were
placed in an oven at 80° C and allowed to completely dry. Once dried, the mass of the sponges
was measured and recorded. Enzymatic sponge mass percent remaining can be viewed in Figure
19.
Results
The degradation was linear for the oxidative through four time points. Clear degradation
advantages were seen for the chitosan sponge that contained PEG, however the purpose was not
to compare sponge type it was to show biodegradable properties relating to chitosan sponges.
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FIGURE 18. Bar graph of mean ± standard deviation of sponge remaining mass as a
percentage when subjected to oxidative mediated testing. Five samples were taken over
the course of 18 hours, every 3.6 hours.
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FIGURE 19. Bar graph of mean ± standard deviation of sponge remaining mass as a
percentage when subjected to lysozyme mediated testing. Five samples were taken every
2 days for a duration of 10 days.
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APPENDIX E: SWELLING RATIO OF CHITOSAN SPONGES
Rationale
Local delivery systems should be able to be loaded with clinician’s choice of antibiotics,
and accept the necessary volume to properly deliver concentrations of antibiotics above the MIC.
Chitosan sponges’ ability to be loaded was determined through implementation of a swelling
ratio study.
Materials and Methods
Sponges were fabricated or obtained as detailed in Appendix A. Sponges (n = 4) were
sectioned (6.25 cm2) and independently weighed. Sectioned sponges were placed in 250 mL
containers large enough for the section to lie flat. Sponges were hydrated with 30 mL of 1X PBS
for 10 minutes. At expiration of the 10 minutes, sponges were removed with efforts taken for
excess fluid to drip before loaded weight was measured. Pre- and post-hydration weights were
used to determine the swelling ratio for each sponge investigated. Results can be seen in Figure
20.
Results
All sponges possess an ability to absorb at least 10 times their initial mass. The amount of
chitosan appears to correlate to an increase in swelling capability.
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FIGURE 20. Scatter plot showing mean ± standard deviation of tested sponges (n = 5)
dry and aqueous-hydrated masses.
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APPENDIX F: CHITOSAN SPONGE CYTOCOMPATIBILTY
Rationale
Any successful local delivery based treatment method must be able to inhibit bacteria
with minimal adverse effects. Sterile sponges were used in the cytocompatibility study phase.
Once the study proved that the proposed combination therapy had good elution profiles and
sponge eluates were active against bacteria cytocompatibility was investigated.
Materials and Methods
The sponges used for this phase were fabricated or obtained as detailed in Appendix A.
The materials used for this experiment are: NIH3T3 cancerous fibroblasts cells, 0.75 cm2 48-well
plates, High Glucose Dulbecco’s Modified Eagle Medium (DMEM) cell media, 96-well plates
(Costar), Promega Cell Titer-Glo Luminescent Cell Viability assay, 70% ethanol, and chitosan
sponges (n = 5). The cells were in media, which consisted of 2 mL DMEM, 10% fetal bovine
serum (FBS), and 1% AB/AM. The 1% AB/AM contained penicillin, streptomycin, and
amphotericin B. Cells were suspended in 6 mL of DMEM cell media and vortexed in preparation
for the cytocompatibility study. NIH3T3 cells were seeded/pipetted into 48-well plates at 150µL
per well and incubated overnight promoting cell attachment to the wells. Controls were tested
therefore 20 wells were seeded with 150µL of cells. After 24 hours, three types of chitosan
sponges (2.0% chitosan, 1.5% chitosan/0.5% PEG, and BioSponge) were added to the wells
containing the cells. Each sponge was sectioned to fit inside the well plates (< 0.75 cm2). After
placing sponges in the wells, an additional 150 µL of DMEM cell media was added to each well
including controls. The plates were then placed in the incubator at 37° C with 5.0% CO2
atmosphere overnight promoting proliferation. Two plates were required due to the time points
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being 24 and 72 hours. Plates were removed at their time point and sponge samples were
removed, media was refreshed every 24 hours.
To perform the Cell Titer Glo luminescence assay, 50 µL of cell-titer was pipetted into
each well and the plate is shaken lightly. Light shaking of the plate mixes the Cell Titer Glo with
the cell media producing a bright yellow color. After the prior step, 50 µL samples were
removed from each well and transferred into a white polystyrene 96-well plate, taking care to
interchange the pipette tip after each well. The 96-well plate was placed in a Gen5 microplate
reader and luminescence at λ = 540 nm was read with its imaging software. This is correlated
with the number of cells remaining because the Cell Titer Glo mixture results in cell lysis thus
generating a luminescent signal proportional to the amount of ATP (adenosine-5-triphosphate)
present. The amount of ATP is directly proportional to the number of cells. In addition, imaging
techniques were used to visually detect cell behavior. Healthy growing cells are viewed as
spindle shaped, branching out and connected. A representative micrograph can be seen in Figure
7, which was similar for both time points and all tested sponges.
Results
Results from luminescence (Figures 21 & 22) and micrographs agree, only one
micrograph displayed due to extreme similarities (Figure 20). This supports the idea that chitosan
sponges are cytocompatible.
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FIGURE 21. Appearance of NIH3T3 cells at 24-hours after
contact with BioSponge.

FIGURE 22. Bar graph displaying mean ± standard deviation of cell viability after
being in contact with sponges (n = 5).
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APPENDIX G: IACUC ANIMAL USE PROTOCOL APPROVAL LETTER
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